<DOC>
	<DOCNO>NCT02976519</DOCNO>
	<brief_summary>The objective study investigate safety , tolerability , pharmacokinetics BI 443651 male female healthy volunteer subject Chronic Obstructive Pulmonary Disease ( COPD ) Cystic Fibrosis ( CF ) .</brief_summary>
	<brief_title>BI 443651 Multiple Rising Dose Healthy Volunteers COPD Subjects , Followed Cross-over CF Subjects</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Inclusion criterion : Healthy volunteer : Signed informed consent Healthy male female subject Women childbearing potential ( WOCBP ) dose confirm menstrual period and/or progesterone level Day3 Day1 Age 18 55 year ( incl . ) Body mass index ( BMI ) 18.5 32.0 kg/m2 ( incl . ) Forced expiratory volume 1 second ( FEV1 ) force vital capacity ( FVC ) equal great 80 % predict normal , screen prior randomisation Chronic Obstructive Pulmonary Disease ( COPD ) : Signed informed consent Males female , diagnosis COPD Women childbearing potential ( WOCBP ) dose confirm menstrual period and/or progesterone level Day 3 Day 1 Age 40 75 year ( inclusive ) Body mass index ( BMI ) 18.5 32.0 kg/m2 ( incl . ) Postbronchodilator FEV1 =/ &gt; 50 % predict normal value screen Postbronchodilator FEV1/FVC &lt; 70 % screen Current exsmokers smoke history 10 pack year Clinical stability define stable respiratory medication , evidence acute upper/lower respiratory tract infection , pulmonary exacerbation require use intravenous ( i.v . ) /oral antibiotic , oral corticosteroid , acute ( serious nonserious ) illness relate COPD Must able perform technically acceptable pulmonary function test ( PFTs ) . Cystic Fibrosis ( Cross part ) : Signed informed consent Males female document diagnosis cystic fibrosis Women childbearing potential ( WOCBP ) dose confirm menstrual period and/or progesterone level Day 3 Day 1 Age 18 55 year ( inclusive ) BMI 18 32.0 kg/m2 ( incl . ) Prebronchodilator FEV1 &gt; /= 70 % predict normal screen prior randomisation Clinical stability define evidence acute upper low respiratory tract infection ; pulmonary exacerbation require use i.v . / oral / inhale antibiotic , oral corticosteroid ; change pulmonary disease therapy ; cycle antibiotic , must initiate within 2 week prior randomisation ; acute ( serious nonserious ) illness relate cystic fibrosis ; infection organism associate rapid decline pulmonary function ( eg , Burkholderia cenocepacia , B dolosa , Mycobacterium abscessus ) . Able perform technically acceptable pulmonary function test ( PFTs ) Further inclusion criterion apply . Exclusion criterion : Any evidence concomitant disease judge clinically relevant investigator include gastrointestinal , hepatic , renal , respiratory* , cardiovascular , metabolic** , immunological , dermatologic , hematologic , neurological psychiatric , oncological , coagulation hormonal disorder determine medical history , examination , clinical investigation screen may , opinion investigator , result following : Put subject risk participation study ; Influence result study ; Cast doubt subject 's ability participate study ( *except chronic obstructive pulmonary disease ( COPD ) cystic fibrosis ( CF ) subject ; COPD subject resolve childhood asthma may include ; CF subject may include concomitant asthma provide stable medication 6 week prior inclusion study . Patients acute bronchopulmonary aspergillosis may include . ** CF subject diabetes allow participate disease good control prior screen assess principal investigator ) Chronic relevant acute infection . History relevant orthostatic hypotension , faint spell , blackout History myocardial infarction ; history acute coronary syndrome History and/or active lifethreatening cardiac arrhythmia , assess investigator Major surgery ( major accord investigator 's assessment ) History chronic kidney disease ( estimate glomerular filtration rate ( EGFR ) &lt; 59 mls/min include correction per ethnicity ) History relevant allergy hypersensitivity ( include allergy trial medication excipients ) Unsuitable vein venipuncture ( instance , vein difficult locate , access puncture , vein tendency rupture puncture ) assess investigator Any finding medical examination ( include blood pressure ( BP ) , pulse rate ( PR ) electrocardiogram ( ECG ) deviate normal judge clinically relevant investigator Any laboratory value outside reference range investigator considers clinical relevance ; Safety laboratory screening , evaluation repeat twice screen . For healthy volunteer , repeat measurement ( i.e . &gt; 2 measurement ) systolic blood pressure outside range 90 140 mmHg , diastolic blood pressure outside range 50 90 mmHg . Volunteers exclude pulse rate outside range 45 90 bpm . A marked baseline prolongation mean QT/QTcF interval ( QTcF interval repeatedly great 450 m male repeatedly great 470 m female ) relevant ECG find screen prior randomisation . A history additional risk factor Torsades de Pointes ( heart failure , hypokalemia , family history Long QT Syndrome ) . Within 10 day prior administration trial medication , use drug might reasonably influence result trial might prolong QT/QTcF interval Intake drug long halflife ( 24hrs ) within 30 day less 10 halflives respective drug prior administration trial medication CF COPD subject treat nonpermitted concomitant medication Current previous participation another interventional trial , include investigational drug administer within 60 day 5 halflives ( whichever longer ) prior screen For healthy volunteer CF subject : current smoker exsmokers less 12 month and/or pack year history 5 year Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>